本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Nurix Therapeutics

25.10
-0.7100-2.75%
盤後25.100.00000.00%19:30 EDT
成交量:132.17萬
成交額:3,359.78萬
市值:25.95億
市盈率:-7.36
高:26.65
開:26.31
低:25.00
收:25.81
52周最高:28.23
52周最低:8.20
股本:1.03億
流通股本:9,504.52萬
量比:1.11
換手率:1.39%
股息:- -
股息率:- -
每股收益(TTM):-3.4102
每股收益(LYR):-3.0514
淨資產收益率:-80.30%
總資產收益率:-40.06%
市淨率:6.45
市盈率(LYR):-8.23

資料載入中...

2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2021/02/16

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/02/16

年度報告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2021/02/16

重要事件披露

8-K - Current report
2021/02/04

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/12/07

重要事件披露

8-K - Current report
2020/10/26

重要事件披露

8-K - Current report
2020/10/14

重要事件披露

8-K - Current report
2020/10/14

季度報告

10-Q - Quarterly report [Sections 13 or 15(d)]
2020/10/14

重要事件披露

8-K - Current report
2020/08/10

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/08/03

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2020/07/24

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2020/07/23

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2020/07/21

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/21

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/20

[修訂]招股説明書

S-1/A [Amend] - General form for registration of securities under the Securities Act of 1933
2020/07/10

SEC問詢函

CORRESP [Cover] - Correspondence
2020/07/02

招股説明書

S-1 - General form for registration of securities under the Securities Act of 1933